Hospital General de Tomelloso

Running trials

• Not yet recruiting

  A pivotal clinical study to investigate the safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis due to Metabolic dysfunction-associated steatohepatitis (MASH)

  2026-525755-82-00· Phase 3· Glaxosmithkline Research & Development Limited· Source

• Not yet recruiting

  A study to investigate safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis (stage F4 fibrosis) due to MASH (NEBULA-2)

  2026-525757-37-00· Phase 3· Glaxosmithkline Research & Development Limited· Source

• Recruiting

  Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)

  NCT07631637· Phase 2· Regeneron Pharmaceuticals· Source

• Recruiting

  A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH

  NCT07221188· Phase 3· GlaxoSmithKline· Source

• Recruiting

  Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of ANB033

  2024-520409-38-00· Phase 1· First Tracks Biotherapeutics Inc.· Source

• Recruiting

  An Adaptive, Dose-Ranging, Phase 2 Study of Eltrekibart Given Alone or in Combination with Mirikizumab for the Treatment of Adult Patients with Moderately to Severely Active Ulcerative Colitis

  2023-507853-13-00· Phase 2· Eli Lilly & Co.· Source

• Active, not recruiting

  Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis

  NCT05583227· Phase 3· AstraZeneca· Source

• Not yet recruiting

  Long-term clinical trial on tolerability, toxicity, pharmacokinetics and molecular mechanisms of action of EPI-EE

  2025-520751-83-00· Phase 1· Hospital General De Tomelloso· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Fatty liver disease (MASLD/MASH)4 recruiting
• Eosinophilic oesophagitis2 recruiting
• Coeliac disease1 recruiting
• Liver cirrhosis1 recruiting

Closed trials

• Active, not recruiting

  A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic Esophagitis

  NCT06598462· Phase 2· Uniquity One (UNI)· Source

• Completed

  A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)

  NCT06465186· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)

  NCT05877547· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  A Multicenter, Randomized, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenance Therapy for Moderately to Severely Active Crohn’s Disease

  2024-513569-38-00· Phase 2/3· Arena Pharmaceuticals Inc.· Source

• Active, not recruiting

  Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE

  NCT06596252· Phase 3· Dr. Falk Pharma GmbH· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Eosinophilic oesophagitis23 works · 5 trials